Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

This study looks at whether glofitamab — a drug that recruits your immune system to attack lymphoma cells — works as a single drug or combined with another cancer drug (polatuzumab vedotin) for people with a rare and aggressive type of lymphoma called transformed follicular lymphoma. **You may be eligible if...** - You are 18 or older - You have been diagnosed with transformed follicular lymphoma - Your lymphoma has relapsed or is no longer responding to treatment - You are well enough to carry out daily activities (good performance status) **You may NOT be eligible if...** - You have active serious infections or uncontrolled other cancers - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.